| Verified against primary record | |
| Approved products, United States | Blood-forming stem cells from umbilical cord blood only; no approved exosome products[1] |
|---|---|
| Australia | Stem cells are regulated as biologicals and cannot be advertised to the public[2] |
| Japan | Provision outside clinical trials requires an advance plan to the Minister and certified committee review[3] |
| Records read | Three regulators, a society guide and a clinic-count study, 30 September 2026 |
| Independently reported | |
| What is counted | 351 businesses at 570 clinics in the United States alone, 2016[4] |
| Bands apply only to the rows beneath them. The clinic count is of supply in one country, not of patients travelling. No figure for travel exists. | |
Stem cell tourism is the term used for travel to obtain cell-based interventions that are not approved where the patient lives. The term is well established. What it names, in terms of measured patient movement, is not.
What is actually approved
The United States Food and Drug Administration states that the only stem cell products approved for use in the country consist of blood-forming stem cells derived from umbilical cord blood, and that there are currently no approved exosome products.[1] An international scientific society’s patient guide puts the position in the same terms: only blood stem cell transplantation is well established, for blood diseases, bone marrow failure and certain immune-cell and metabolic disorders, alongside one European-approved corneal treatment, and other stem cell treatments remain experimental.[5]
That guide defines an unproven treatment as one that has not been tested through formal or regulated clinical trials, and lists the marketing signals that distinguish one: reliance on patient testimonials rather than controlled studies, a single treatment offered for multiple unrelated diseases, unclear documentation of the cell source, claims of no risk, high cost with hidden fees, and assertions that regulatory approval is not needed. It adds that it is not customary to pay to be in a clinical trial, and that being charged is often a warning sign.[5]
Regulation outside the United States and Europe
Two other frameworks are worth recording because they take different approaches. Australia’s regulator states that stem cells are a type of human cell or tissue product regulated as biologicals and cannot be advertised to the public, with criminal and civil penalties for non-compliance.[2] That is a control on marketing rather than on provision.
Japan took the opposite route, bringing provision itself into a framework. Its Act on the Safety of Regenerative Medicine, Act No. 85 of 27 November 2013 as later amended, applies to medical care using regenerative medicine technology outside clinical trials, which is precisely the fee-charging clinic setting. It sorts technologies into three risk classes according to the severity and certainty of their effects, and requires a provider to submit a provision plan to the Minister in advance, obtain review by a certified committee confirming compliance with provision standards, report adverse events, submit periodic status updates, maintain records and ensure informed consent.[3]
The measurement problem
A 2016 study assessed the direct-to-consumer industry by counting businesses. Using internet keyword searching, text mining and content analysis of company websites, it identified 351 United States businesses marketing stem cell interventions directly to consumers, offered at 570 clinics, with the largest concentrations in California at 113 clinics, Florida at 104 and Texas at 71.[4]
This is the central observation of the entry. The literature measures supply, meaning businesses and clinics, and not travel, meaning patients. No count of patients travelling for these interventions was located. Further, the domestic figure cuts against the premise of the term itself: a country with 570 such clinics is not one where obtaining the intervention requires leaving.
The same point applies to the regulatory warnings. Five American consumer and enforcement pages were read for a related entry on this site and none mentions travelling abroad; the warnings concern products marketed and administered domestically and bought online. Harm following treatment obtained abroad is documented, but thinly: a 2021 case report describes a man with end-stage kidney failure who received an infusion at a clinic in Ukraine in December 2018 and died some months later.[6] It is a single case and supports no claim about frequency.
See also
- Medical travel for unavailable treatments, the wider category and the routes that need no travel
- Longevity tourism, an adjacent sector selling overlapping interventions
- Medical tourism and public health, for the regulatory response to unproven practice
- Medical travel for rare diseases, whose patients are a frequent target of this marketing
References
- United States Food and Drug Administration. Consumer Alert on Regenerative Medicine Products Including Stem Cells and Exosomes. 9 April 2024. Verified against primary record: regulator page opened and read. Retrieved 30 September 2026.
- Therapeutic Goods Administration, Australia. Advertising stem cell and other human cell or tissue products. Page carries no date. Verified against primary record: regulator guidance opened and read. Retrieved 30 September 2026.
- Government of Japan. Act on the Safety of Regenerative Medicine, Act No. 85 of 27 November 2013, as last amended by Act No. 68 of 2022. Verified against primary record: official English translation opened and read; such translations carry an unofficial-translation disclaimer. Retrieved 30 September 2026.
- Turner L, Knoepfler P. Selling Stem Cells in the USA: Assessing the Direct-to-Consumer Industry. Cell Stem Cell, 2016; data collected 2015 to 2016. Independently reported: peer-reviewed study. Retrieved 30 September 2026.
- International Society for Stem Cell Research. The ISSCR Guide to Stem Cell Treatments. Version 12, February 2024. Verified against primary record: the society’s own patient publication opened and read. Retrieved 30 September 2026.
- Veceric-Haler Z, Borstnar S, Luzar B, Jerse M, Kojc N. Multiorgan failure with fatal outcome after stem cell tourism. European Journal of Medical Research, vol. 26, article 5, 2021. Independently reported: peer-reviewed case report. Retrieved 30 September 2026.
Sourcing note: the three regulators’ pages, the society guide, the industry study and the case report were opened and read on 30 September 2026. The business and clinic counts are for the United States only; a comparable global count exists in the literature but could not be opened for this entry, so no international figure is given. The finding that the literature measures supply rather than travel is reported as the entry’s central point rather than presented as a gap. The case report is a single case and is labelled as one.